Loading…
Loading…
HZNP (Horizon Therapeutics Public Limited Company) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
HZNP does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for HZNP and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for HZNP and 80,000+ other tickers.
See exactly how HZNP's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for HZNP and 80,000+ other tickers.
Horizon Therapeutics Public Limited Company operates as a biotechnology enterprise, primarily concentrating on the identification, refinement, and commercialization of pharmaceutical products designed to address significant medical needs for individuals afflicted by rare, autoimmune, and severe inflammatory conditions. The company's operations are divided into two principal divisions: Orphan and Inflammation. Its extensive product lineup features twelve distinct medications, targeting therapeutic areas such as rare diseases, gout, ophthalmic conditions, and various forms of inflammation…
Amgen has not been a great performer in the last two years. Investors became and remain skeptical of MariTide's prospects in obesity, type 2 diabetes, and other related indications. I continue to see MariTide's monthly dosing as a strong selling point and expect that addition of dose escalation to phase 3 trial design will improve its tolerability.
Amgen on Tuesday said its adjusted fourth-quarter profit rose 15%, driven by a 20% increase in revenue following the biotechnology company's October acquisition of rare disease drugmaker Horizon Therapeutics.
CNBC's Jim Cramer pointed out the numerous mergers and acquisitions across the biopharma industry.
Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provide a safety net in uncertain economic conditions.
We believe that AMGN has overpaid for HZNP's pipeline, since most of its upside potential is attributed to price increases instead of the expanding TAM. The growing debt may also pose headwinds to its profitability and subsequently, dividend growth and balance sheet deleveraging. Then again, it appears that Mr. Market is still convinced about AMGN' profitable growth ahead, as demonstrated by the stock's immense bullish support.